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Abstract
Purpose: To assess the clinical usefulness of the European Thyroid Imaging and Reporting Data System (EU-TIRADS) 
in the valuation of thyroid nodules malignancy in reference to post-surgery histological results.
Material and methods: Pre-operative ultrasound was performed in consecutive patients admitted for thyroid surgery 
between June 2017 and January 2018. Thyroid nodules were classified according to EU-TIRADS to five groups: 1-5. 
At least one fine-needle aspiration biopsy (FNAB)/patient (dominant or suspected nodule) was performed in an out-
patient clinic. The final diagnosis was based on the histological result. The percentage of cancers in each EU-TIRADS 
group was evaluated. Finally, sensitivity, specificity, accuracy, as well as positive and negative predictive values for 
malignancy were assessed.
Results: Fifty-two patients with a total of 140 thyroid nodules (median: 3 nodules/thyroid [minimum-maximum: 1-6]) 
were enrolled in the study. Thyroid cancer was diagnosed in 0% (0/6) in EU-TIRADS 2; 0% (0/92) in EU-TIRADS 3; 
5.9% (2/34) in EU-TIRADS 4, and 75% (6/8) in EU-TIRADS 5. In nodules assessed as EU-TIRADS ≥ 4 sensitivity, 
specificity, positive and negative predictive values for malignancy were, respectively: 75% (CI 95%: 40.7-93.5), 94.1% 
(CI 95%: 86.0-98.5), 75% (CI 95%: 40.7-93.5), and 94.1% (CI 95%: 86.0-98.5).
Conclusions: EU-TIRADS is a valuable and simple tool for assessment of the risk of malignancy of thyroid nodules 
and demonstrates a high ultrasound correlation with histological post-surgery results. FNAB should be performed 
in all nodules assessed as EU-TIRADS ≥ 4, due to higher risk of malignancy. 
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Introduction
The widespread use of imaging techniques has generated 
increasing detection rates of thyroid nodules. The preva-
lence of thyroid nodules is still high and ranges from 50% 
to 60% in healthy people [1]. Ultrasound (US) is current-
ly the best detection tool of choice available for the initial 
work-up of thyroid nodules. The main aim of thyroid US 
examination is to distinguish benign nodules from those 
suspicious for malignant features and requiring further 
investigation. Approximately 90% of thyroid lesions are 
benign, and 95% are asymptomatic during recognition 
and further follow-up [2]. Fine-needle aspiration biopsy 
(FNAB) is used to differentiate between nodules that re-
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quire surgery and those that can be followed-up. Appro-
ximately 10-20% of FNAB are non-diagnostic and need 
to be repeated [3]. The limitations of FNAB include inde-
terminate or follicular lesions. The prevalence of unneces-
sary thyroid surgery is still a therapeutic problem [4]. For 
all these reasons there was a need to establish some basic 
criteria to select nodules for FNAB to minimise costs and 
maximise benefits. 
US uses a wide range of features that present different 
sensitivity and specificity in prediction of thyroid cancer. 
However, none of them could be used alone in detecting 
or rejecting malignancy efficiently. The main disadvan-
tage of US examination is relatively low specificity and 
substantial inter-operator variability [5,6]. To minimise 
the impact of these limitations, attempts are being made 
to develop and refine a standardised system. 
The American Association of Clinical Endocrinol-
ogists and American Thyroid Association have created 
a practical clinical statement, for better communication 
between ultrasound practitioners and clinicians, called 
Thyroid Imaging, Reporting, and Data System (TIRADS) 
classification. It was first introduced by Horvath et al. 
[7], originating from the Breast Imaging Reporting and 
Data System [8]. Since its introduction, several versions 
of TIRADS have been endorsed by international medical 
societies to estimate the final assessment and management 
of thyroid lesions. All of them classify nodules based on 
suspicious ultrasound features related to composition, 
echogenicity, shape, margin, and echogenic foci.
In 2017 the European Thyroid Association developed 
a new and simple European Thyroid Imaging and Report-
ing Data System (EU-TIRADS), which classifies the risk 
of malignancy of thyroid nodules in adults to the follow-
ing categories: benign, low-, intermediate-, and high-risk 
(e.g. EU-TIRADS 1 is a normal exam, EU-TIRADS 5 
means high risk of malignancy) [9]. The aim of this study 
was to assess the clinical usefulness of EU-TIRADS in the 
valuation of thyroid nodule malignancy in reference to 
post-surgery histological results.
Material and methods
Patients
This prospective study was conducted at an academic re-
ferral centre between 06.2017 and 01.2018. Patients were 
admitted to the Department of General and Endocrine 
Surgery for thyroid or parathyroid surgery. The decision 
about surgical treatment was made before admission to 
the hospital, based on clinical, US, laboratory, and FNAB 
evaluation. Patients were consecutively recruited to the 
study if they fulfilled the following criteria: 1) preopera-
tive US reassessment of the neck performed by two cer-
tified ultrasonographers; 2) preoperative FNAB of dom-
inant or suspicious lesion; 3) surgical thyroid resection 
with histological evaluation.
All the procedures were performed in accordance with 
the Helsinki Declaration of 1975, as revised in 2000, and 
with the ethical standards of the local Research Ethics 
Committee.
Ultrasound examination
All patients were reassessed with a preoperative US of the 
neck for nodal staging by two certified ultrasonographers 
(AS and MŻ) (certificate of Polish Ultrasound Society) with 
two and 15 years of experience, respectively, in thyroid US. 
US was performed in the Department of Endocrinology 
a few days before the thyroid surgery. All the US scans were 
performed using a Hitachi Avius Medical ultrasound tech-
nique system equipped with a 7.5-12 MHz high-frequency 
linear array transducer. Thyroid US procedures were per-
formed on the basis of the Ultrasound Examination Stand-
ards of the Polish Ultrasound Society (2014) [10]. The neck 
was scanned in sagittal, transverse, and oblique sections to 
optimally visualise both lobes of thyroid, isthmus, and carot-
id arteries, as well as internal jugular veins. All images were 
examined on real-time two-dimensional B-mode grey-scale 
and Doppler imaging. All obtained sonograms were saved 
in a picture archiving and communication system. The US 
examination study did not change the management of sur-
gical interventions. The interobserver agreement was meas-
ured using a weighted kappa statistic with 95% confidence 
intervals (CI 95%). Levels of agreement included values: ≤ 0 
as no agreement, 0.01-0.20 as slight, 0.21-0.40 as fair, 0.41-
0.60 as moderate, 0.61-0.80 as substantial, and 0.81-1.00 as 
almost perfect agreement. In this study the interobserver 
agreement was almost perfect.
EU-TIRADS
According to the EU-TIRADS, we assessed the presence of 
five equally-weighted nodule features (irregular/non-oval 
shape, irregular margins, microcalcifications, marked hy-
poechogenicity, solid component), and assigned the lesion 
to one of five categories based on the number of suspi-
cious features. To define and specify each US pattern, the 
following variables were considered: composition (solid, 
predominantly solid, predominantly cystic, simple cyst, 
spongiform), echogenicity (hyperechoic, isoechoic, hypo-
echoic, markedly hypoechoic), margins (circumscribed, 
non-circumscribed), and calcifications (absent, micro-
scopic, macroscopic – the latter including eggshell calcifi-
cations). Other parameters were also recorded: 1) nodule 
diameters (transverse, anteroposterior, and longitudinal); 
and 2) nodule shape (oval [wider than tall], non-oval 
[taller than wide], irregular).
Cervical lymph nodes were evaluated for their size, loss 
of the central, echogenic hilum, the presence of irregular and 
indistinct margin, microcalcifications, and necrotic changes.
Normal thyroid gland was classified as EU-TIRADS 1, 
a benign nodule as EU-TIRADS 2 (Figure 1A,B), a nod-
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Figure 1. Representative images of EU-TIRADS categories. A) EU-TIRADS 2: 
a well-defined oval cystic nodule; B) EU-TIRADS 2: a multiple spongiform 
cystic nodule; C) EU-TIRADS 3: a large well-defined normoechoic nodule; 
D) EU-TIRADS 3: a hyperechoic nodule. E) EU-TIRADS 4: a well-defined mild 
hypoechoic nodule; F, G) EU-TIRADS 5: an ill-defined oval hypoechoic nodule 
surrounded by incomplete halo sign with a microcalcification inside (arrow)
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ule with low suspicion for malignancy as EU-TIRADS 3 
(Figure 1C,D), a nodule with intermediate suspicion for 
malignancy as EU-TIRADS 4 (Figure 1E), and a nodule 
highly suggestive of malignancy as EU-TIRADS 5 (Figu-
re 1F,G).
Fine-needle aspiration biopsy
FNAB of dominant or suspicious lesions in US (at least in 
one thyroid lesion) was performed before the admission 
to the hospital. The majority of FNABs were completed in 
the outpatient clinic before admission to the hospital. The 
Bethesda System for reporting thyroid cytopathology was 
used in the classification of cytology reports.
Surgery
Thyroid surgeries were performed in the Department 
of General and Endocrine Surgery. Total thyroidecto-
my was performed in 40 patients (eight with suspicion 
of carcinoma in FNAB, 32 with multinodular goitre), 
lobectomy in nine (17.3%) patients, and lobectomy plus 
isthmectomy in three (5.8%) patients. Total thyroidecto-
my with neck exploration was done in seven (13.5%) pa-
tients, of these lymph nodule dissection was performed 
in three patients.
Histological evaluation
Histological evaluation was performed by one pathologist 
(MM). All of the nodules analysed in US were separately 
assessed in histological examination.
Statistical analysis
Statistical analysis was performed using the statistical 
program STATISTICA 10 (StatSoft Inc.). Qualitative 
characteristics were described along with their percent-
age distributions. For quantitative variables, averages and 
standard deviation (SD) or median (range) were used. The 
consensus decisions were compared with surgical histol-
ogy reports (reference standard). Specificity, sensitivity, 
positive predictive value (PPV), and negative predictive 
value (NPV) (with 95% confidence interval [CI 95%]) 
were calculated to evaluate the reliability of EU-TIRADS 
classification in differentiation between benign and ma-
lignant features.
Results
Fifty-two patients (44 female) with mean age of 55 ± 14 years 
were enrolled in the study. Patient characteristics includ-
ing age, sex, indications for surgery, clinical symptoms, 
thyrotropin, and free thyroid hormone levels are present-
ed in Table 1.
Ultrasound evaluation 
The total amount of thyroid nodules found in US was 140 
(median: 3 nodules/patient [minimum-maximum: 1-6]). 
The details of US examination are shown in Table 2. 
EU-TIRADS
The overall distribution in EU-TIRADS categories was as fol-
lows: six EU-TIRADS 2 (4.3%), 92 EU-TIRADS 3 (65.7%), 
34 EU-TIRADS 4 (24.3%), and eight EU-TIRADS 5 (5.7%) 
(Table 3).
Fine-needle aspiration biopsy
FNAB of 63 nodules was performed (details in Table 3). 
Among the examined nodules, 37 (58.7%) were assessed 
as benign, four (6.3%) were suspected for malignancy, 
and two (3.2%) were reported as malignant. The rest of 
them (20 [31.7%]) were categorised as III or IV accord-
ing to the Bethesda system. In the final histological ex-
amination, thyroid cancer was not recognised in nodules 
with category III in FNAB evaluation, in two among six 
nodules with category IV (anaplastic and follicular can-
cer), and in all nodules with category V (medullary and 
papillary cancer) and with category VI (lymphoma, an-
aplastic cancer). 
Histological evaluation
Histological examination revealed 132 (94.3%) benign 
nodules (adenomas, hyperplastic, cystic, and colloid nod-
ules) and eight (5.7%) cancers (details in Table 4).
Comparison of ultrasound and histological evaluation
The US evaluation of selected patterns of thyroid nod-
ules with comparison between histologically recognised 
malignant and benign nodules is summarised in Table 2. 
Solid composition, hypoechogenicity, microcalcifications, 
“taller than wide”, irregular shape, and non-circumscribed 
margins were more frequent ultrasound features in malig-
nant lesions than in benign nodules. Similarly, predomi-
nantly cystic component, simple cyst, spongiform, hyper-/
isoechogenic, oval, and with circumscribed margins nod-
ules were associated more often with the histological diag-
nosis of benign lesions. There was no significant difference 
between the size of benign (16 ± 17.5 mm) and malignant 
nodules (17.5 ± 6.8 mm).
Comparison of EU-TIRADS and histological evaluation
The percentage of malignancy for each EU-TIRADS cate-
gory was as follows: 0% (0/6) in EU-TIRADS 2; 0% (0/92) 
in EU-TIRADS 3; 5.9% (2/34) in EU-TIRADS 4; and 75% 
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Table 1. Demographic and clinical profile of patients
Factor All patients
(n = 52)
Patients with benign  
nodules (n = 44)
Patients with malignant 
nodules (n = 8)
Age (years)
Mean 55 ± 14 56 ± 12 35 ± 16
< 30 3 (5.8%) 1 (2.3%) 2 (25%)
30-39 9 (17.3%) 7 (15.9%) 2 (25%)
40-49 9 (17.3%) 9 (20.5%) –
50-59 10 (19.2%) 9 (20.5%) 1 (12.5%)
60-69 15 (28.8%) 14 (31.8%) 1 (12.5%)
≥ 70 6 (11.5%) 4 (9.1%) 2 (25%)
Sex
Female 44 (84.6%) 39 (88.6%) 5 (62.5%)
Male 8 (15.4%) 5 (11.4%) 3 (37.5%)
Clinical symptoms
Goitre compression 25 (48.1%) 24 (54.5%) 1 (12.5%)
Laryngeal nerve palsy 2 (3.8%) – 2 (25%)
Rapidly enlarging mass 4 (7.7%) 2 (4.5%) 2 (25%)
Hyperthyroidism 5 (9.6%) 4 (9.1%) 1 (12.5%)
Cervical lymphadenopathy 2 (3.8%) – 2 (25%)
Thyroid function
TSH (0.27-4.2 mIU/l) 1.33 ± 0.84 1.31 ± 0.85 1.44 ± 0.78
FT4 (12-22 pmol/l) 16.30 ± 2.45 16.15 ± 2.43 17.70 ± 2.21
FT3 (3.1-6.8 pmol/l) 4.84 ± 0.76 4.84 ± 0.77 5.25 ± 0.68
Indications for surgery
Suspicion of malignancy 12 (23.1%) 6 (13.6%) 6 (75%)
Goitre size and signs of compression 20 (38.5%) 19 (43.2%) 1 (12.5%)
Toxic multinodular goitre 5 (9.6%) 4 (9.1%) 1 (12.5%)*
Cosmetic problems 2 (3.8%) 2 (4.5%) –
Other
Multinodular goitre and primary 
hyperparathyroidsm
13 (25%) 13 (29.5%) –
FT3 – free triiodothyronine, FT4 – free thyroxine, TSH – thyrotropin
*Incidental, histologically detected follicular microcarcinoma
(6/8) in EU-TIRADS 5. In nodules assessed as EU-TIRADS 
≥ 4, predictive values for malignancy were assessed: sen-
sitivity of 75% (CI 95%: 40.7-93.5); specificity of 94.1% 
(CI 95%: 86.0-98.5); PPV of 75% (CI 95%: 40.7-93.5); and 
NPV of 94.1% (CI 95%: 86.0-98.5).
Discussion
For the last nine years several attempts have been made to 
create a standardised systematic categorisation of thyroid 
nodules according to their risk of malignancy, in order to 
optimise focal lesion management through US follow-up, 
cytological analysis, and surgical treatment with patho-
logical verification. 
In 2009, Horvath et al. and then Park et al. [7,11], 
first presented the Thyroid Imaging Reporting and Data 
System (TIRADS). The system, based on 10 US patterns 
proposed in a prospective study by Horvath et al. did not 
cover the entire spectrum of lesions that may occur in 
thyroid nodules, especially multinodular goitre. The clas-
sification described in a retrospective study by Park et al., 
based on a formula for calculation of TIRADS, seemed to 
be too complicated for common use by US practitioners. 
In 2011 Kwak et al. [12] published another approach for 
TIRADS classification, a more accurate tool in daily prac-
tice for the evaluation of thyroid cancer in multinodular 
goitre, particularly to select cases that require biopsy [13]. 
Russ et al. [14] presented in 2013, in a large prospective 
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Table 2. Ultrasound features of benign and malignant nodules
Ultrasound features All nodules
(n = 140, 100%)
Benign nodules
(n = 132, 94.3%)
Malignant nodules
(n = 8, 5.7%)
Composition
Solid 41 34 (25.8%) 7 (87.5%)
Predominantly solid 62 61 (46.2%) 1 (12.5%)
Predominantly cystic 30 30 (22.7%) –
Simple cyst 3 3 (2.3%) –
Spongiform 4 4 (3.1%) –
Echogenicity
Hypo-/markedly hypo- 73 65 (49.2%) 8 (100%)
Hyper-/iso- 67 67 (50.8%) –
Margins
Circumscribed 134 132 (100%) 2 (25%)
Non-circumscribed 6 – 6 (75%)
Calcifications
Microcalcifications 5 2 (1.5%) 3 (37.5%)
Macrocalcifications 17 16 (12.1%) 1 (12.5%)
None 118 114 (86.4%) 4 (50%)
Shape
Oval (wider than tall) 134 131 (99.2%) 3 (37.5%)
Non-oval (taller than wide 6 1 (0.8%) 5 (62.5%)
Irregular 8 – 8 (100%)
Lymphatic nodes
Suspected for malignancy 2 – 2 (25%)
n – number of nodules, US – ultrasound
Table 3. The results of EU-TIRADS classification
EU-TIRADS
n (%)
Nodule size (mm), 
median (range)
Preoperative FNAB
n (%)
Histopathological findings
n (%)
EU-TIRADS 2
6 (4.3%)
19.5 (6.0-41.0) II – 3 (4.8%) Colloid nodule – 3 (50%)
Simple cyst – 3 (50%)
EU-TIRADS 3
92 (65.7%)
18.0 (5.0-47.5) II – 28 (44.4%)
III – 7 (11.1%)
IV – 1 (1.6%)
Colloid nodule – 66 (71.7%)
Hyperplastic nodule – 25 (27.2%)
Adenoma – 2 (2.2%)
EU-TIRADS 4
34 (24.3%)
11.6 (5.0-29.0) II – 9 (14.3%)
III – 4 (6.3%)
IV – 3 (4.8%)
V – 1 (1.6%)
VI – 1 (1.6%)
Colloid nodule – 20 (58.8%)
Hyperplastic nodule – 12 (35.3%)
Adenoma – 2 (5.9%)
Papillary cancer – 1 (2.9%)
Anaplastic cancer – 1 (2.9%)
EU-TIRADS 5
8 (24.3%)
17.8 (14.2-34) IV – 2 (3.2%)
V – 3 (4.8%)
VI – 1 (1.6%)
Hyperplastic nodule – 2 (25%)*
Lymphoma – 1 (12.5%)
Papillary cancer – 2 (25%)
Follicular cancer – 2 (25%)
Medullary cancer – 1 (12.5%)
*FNAB not performed
EU-TIRADS – European Thyroid Imaging Reporting and Data System; FNAB – fine-needle aspiration biopsy; n – number of nodules
 Risk valuation of thyroid nodules malignancy with EU-TIRADS
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Table 4. Histological evaluation (n = 140)
Histological 
evaluation
Nodules 
n (%)
Ultrasonography
Colloid 
nodule
89 (63.6%) Solid – 19 (21.3%)
Predominantly solid – 38 (42.7%)
Predominantly cystic – 21 (23.6%)
Simple cyst – 3 (3.4%)
Spongiform – 8 (8.9%)
Hypo-/markedly hypoechoic – 14 (15.7%)
Hyper-/isoechoic – 75 (84.3%)
Hyperplastic 
nodule
39 (27.9%) Solid – 12 (31.6%)
Predominantly solid – 19 (48.7%)
Predominantly cystic – 8 (21.1%)
Hypo-/markedly hypoechoic – 6 (15.8%)
Hyper-/isoechoic – 32 (8.2%)
Adenoma 4 (2.9%) Solid – 4 (100%)
Hypo-/markedly hypoechoic – 4 (100%)
Follicular 
cancer
2 (1.4%) Solid – 1 (50%)
Predominantly solid – 1 (50%)
Hypo-/markedly hypoechoic – 2 (100%)
Non-circumscribed – 1 (50%)
Papillary 
cancer
3 (2.1%) Solid – 3 (100%)
Hypo-/markedly hypoechoic – 3 (100%)
Non-circumscribed – 3 (100%)
Medullary 
cancer
1 (0.7%) Solid – 1 (100%)
Hypo-/markedly hypoechoic – 1 (100%)
Anaplastic 
cancer
1 (0.7%) Solid – 1 (100%)
Hypo-/markedly hypoechoic – 1 (100%)
Non-circumscribed – 1 (100%)
Lymphoma 1 (0.7%) Solid – 1 (100%)
Hypo-/markedly hypoechoic – 1 (100%)
Non-circumscribed – 1 (100%)
n – number of nodules
study based on the results of 4550 thyroid nodules, a sim-
ple classification that included only five suspicious sono-
graphic patterns, together with optional elastography. In 
2017, the American College of Radio logy Thyroid Imag-
ing Reporting and Data System (ACR TI-RADS) was pub-
lished [15]. Unlike other guidelines, the ACR TI-RADS 
does not recommend FNAB of nodules with benign US 
characteristics regardless of size. The novel EU-TIRADS 
classification created recently by the European Thyroid 
Association assesses the presence of five equally-weight-
ed lesion patterns and assigns the nodule to one of five 
categories, based on the number of suspicious features. 
This system is both practical and accurate.
To our knowledge, our study is the first prospective 
trial that assesses EU-TIRADS classification in the cor-
relation with histological findings received from surgical 
specimens. 
Among nodules evaluated as EU-TIRADS 2 or 3 we did 
not find any cancer. In nodules assessed as EU-TIRADS 4 
and 5 we diagnosed thyroid carcinoma in two (6%) and six 
(75%) nodules, respectively. These results are in accordance 
with EU-TIRADS statement: FNAB is not necessary in 
EU-TIRADS 2, but should be performed in EU-TIRADS 4 
and 5. In EU-TIRADS 3 FNAB should be performed only 
for nodules > 20 mm [9]. 
With a cut-off point at EU-TIRADS ≥ 4, sensitivity, 
specificity, positive predictive value (PPV), and negative 
predictive value (NPV) for recognition of nodules malig-
nancy were: 75%, 94.1%, 75%, and 94.1%, respectively. In 
the prospective validation of TIRADS classification per-
formed by Horvath et al. [16] in 502 resected thyroid 
nodules with a cut-off point at TIRADS ≥ 4 to perform 
FNAB, the specificity was lower (74.4%), but the sensitiv-
ity, PPV, and NPV were higher (99.6%, 82.1%, and 99.4%, 
respectively). According to the results described by Russ 
et al. [14] for TIRADS grey-scale score in combination 
with cytological results sensitivity, specificity, and negative 
predictive value were as follows: 95.7%, 61%, and 99.7%, 
respectively.
Additionally, we found that solid composition, hypo-
echogenicity, microcalcification, “taller than wide”, irreg-
ular shape, and non-circumscribed margins were more 
frequent ultrasound features in malignant lesions. Nodules 
with predominantly cystic component, simple cyst, spon-
giform, hyper-/isoechogenic, oval, and with circumscribed 
margins were associated with the histological diagnosis of 
benign lesions. This is in accordance with the results of 
previous studies [17-20].
The limitations of this study include: (i) relative small 
sample size; (ii) small number of thyroid cancers; and 
(iii) the lack of US examination with the usage of elasto-
graphy. It would be interesting to compare the results 
with those presented by Russ et al. [14], Migda et al. [21], 
and Dobruch-Sobczak et al. [22]. According to Gietka 
et al. [23], Wolinski et al. [24], and Zhao et al. [25], real- 
time elastography, shear wave elastography, and three- 
dimensional shear wave elastography are useful in select-
ing nodules to FNAB. However, other authors reported 
clearly that grey-scale with elastography has poorer results 
for discriminating benign from malignant thyroid lesions 
in comparison to single grey-scale assessment [26-28].
Conclusions
To conclude, EU-TIRADS is a valuable and simple tool 
in assessing the malignancy of thyroid nodules, which 
demonstrates a high clinical correlation with histological 
results. Because of its high sensitivity it can be used in 
selecting nodules with a high risk of cancer. EU-TIRADS 
improves qualification for surgical treatment and leads to 
the avoidance of unnecessary procedures such as FNAB 
of benign thyroid nodules.
Conflict of interest
The authors report no conflict of interest. 
Anna Skowrońska, Justyna Milczarek-Banach, Wiesław Wiechno et al.  
e586 © Pol J Radiol 2018; 83: e579-e586
References
1.  Gharib H, Papini E, Garber JR, et al. American Association of Clini-
cal Endocrinologists, American College of Endocrinology, and As-
sociazione Medici Endocrinologi Medical Guidelines for Clinical 
Practice for The Diagnosis and Management of Thyroid Nodules 
– 2016 Update. Endocr Pract 2016; 22: 622-639.
2.  Durante C, Grani G, Lamartina L, et al. The diagnosis and manage-
ment of thyroid nodules: a review. JAMA 2018; 319: 914-924.
3.  Chow LS, Gharib H, Goellner JR, et al. Nondiagnostic thyroid 
fine-needle aspiration cytology: management dilemmas. Thyroid 2001; 
11: 1147-1151.
4.  Jarząb B, Dedecjus M, Słowińska-Klencka D, et al. Guidelines of 
Polish National Societies Diagnostics and Treatment of Thyroid 
Carcinoma. 2018 Update. Endokrynol Pol 2018; 69: 34-74.
5.  Ko SY, Lee HS, Kim EK, et al. Application of the Thyroid Imaging 
Reporting and Data System in thyroid ultrasonography interpretation 
by less experienced physicians. Ultrasonography 2014; 33: 49-57.
6.  Lee HJ, Yoon DY, Seo YL, et al. Intraobserver and interobserver 
variability in ultrasound measurements of thyroid nodules. J Ultra-
sound Med 2018; 37: 173-178.
7.  Horvath E, Majlis S, Rossi R, et al. An ultrasonogram reporting sys-
tem for thyroid nodules stratifying cancer risk for clinical manage-
ment. J Clin Endocrinol Metab 2009; 94: 1748-1751.
8.  Vanel D. The American College of Radiology (ACR) Breast Imaging 
and Reporting Data System (BI-RADS): a step towards a universal 
radiological language? Eur J Radiol 2007; 61: 183.
9.  Russ G, Bonnema SJ, Erdogan MF, et al. European Thyroid Associ-
ation Guidelines for Ultrasound Malignancy Risk Stratification of 
Thyroid Nodules in Adults: The EU-TIRADS. Eur Thyroid J 2017; 6: 
225-237.
10. Trzebińska A, Dobruch-Sobczak K, Jakubowski W, et al. Standards 
of the Polish Ultrasound Society – update. Ultrasound examination 
of thyroid gland and ultrasound-guided thyroid biopsy. J Ultrason 
2014; 14: 49-60.
11. Park JY, Lee HJ, Jang HW, et al. A proposal for a thyroid imaging 
reporting and data system for ultrasound features of thyroid carci-
noma. Thyroid 2009; 19: 1257-1264.
12. Kwak JY, Han KH, Yoon JH, et al. Thyroid imaging reporting and 
data system for US features of nodules: a step in establishing better 
stratification of cancer risk. Radiology 2011; 260: 892-899.
13. Migda B, Migda M, Migda MS, et al. Use of the Kwak Thyroid Image 
Reporting and Data System (K-TIRADS) in differential diagnosis of 
thyroid nodules: systematic review and meta-analysis. Eur Radiol 
2018; 28: 2380-2388.
14. Russ G, Royer B, Bigorgne C, et al. Prospective evaluation of thyroid 
imaging reporting and data system on 4550 nodules with and with-
out elastography. Eur J Endocrinol 2013; 168: 649-655.
15. Tessler FN, Middleton WD, Grant EG, et al. ACR Thyroid Imaging, 
Reporting and Data System (TI-RADS): White Paper of the ACR 
TI-RADS Committee. J Am Coll Radiol 2017; 14: 587-595.
16. Horvath E, Silva CF, Majlis S, et al. Prospective validation of the 
ultrasound based TIRADS (Thyroid Imaging Reporting And Data 
System) classification: results in surgically resected thyroid nodules. 
Eur Radiol 2017; 27: 2619-2628.
17. Brito JP, Gionfriddo MR, Al Nofal A, et al. The accuracy of thyroid 
nodule ultrasound to predict thyroid cancer: systematic review and 
meta-analysis. J Clin Endocrinol Metab 2014; 99: 1253-1263.
18. Remonti LR, Kramer CK, Leitão CB, et al. Thyroid ultrasound fea-
tures and risk of carcinoma: a systematic review and meta-analysis 
of observational studies. Thyroid 2015; 25: 538-550.
19. Campanella P, Ianni F, Rota CA, et al. Quantification of cancer risk 
of each clinical and ultrasonographic suspicious feature of thyroid 
nodules: a systematic review and meta-analysis. Eur J Endocrinol 
2014; 170: R203-211.
20. Whittle C, García M, Horvath E, et al. Thyroid microcalcifications 
in the absence of identifiable nodules and their association with thy-
roid cancer. J Ultrasound Med 2018; 38: 97-102.
21. Migda B, Migda M, Migda AM, et al. Evaluation of Four Variants of 
the Thyroid Imaging Reporting and Data System (TIRADS) Clas-
sification in Patients with Multinodular Goiter – initial study. En-
dokrynol Pol 2018; 69: 156-162.
22. Dobruch-Sobczak K, Zalewska EB, Gumińska A, et al. Diagnostic 
performance of shear wave elastography parameters alone and in 
combination with conventional b-mode ultrasound parameters for 
the characterization of thyroid nodules: a prospective, dual-center 
study. Ultrasound Med Biol 2016; 42: 2803-2811.
23. Gietka-Czernel M, Kochman M, Bujalska K, et al. Real-time ultra-
sound elastography – a new tool for diagnosing thyroid nodules. 
Endokrynol Pol 2010; 61: 652-657.
24. Woliński K, Szczepanek-Parulska E, Stangierski A, et al. How to 
select nodules for fine-needle aspiration biopsy in multinodu-
lar goitre. Role of conventional ultrasonography and shear wave 
elastography – a preliminary study. Endokrynol Pol 2014; 65: 
114-118.
25. Zhao CK, Chen SG, Alizad A, et al. Three-dimensional shear wave 
elastography for differentiating benign from malignant thyroid nod-
ules. J Ultrasound Med 2018; 37: 1777-1788.
26. Moon HJ, Sung JM, Kim EK, et al. Diagnostic performance of gray-
scale US and elastography in solid thyroid nodules. Radiology 2012; 
262: 1002-1013.
27. Bojunga J, Herrmann E, Meyer G, et al. Real-time elastography for 
the differentiation of benign and malignant thyroid nodules: a me-
ta-analysis. Thyroid 2010; 20: 1145-1150.
28. Cantisani V, D’Andrea V, Biancari F, et al. Prospective evaluation of 
multiparametric ultrasound and quantitative elastosonography in 
the differential diagnosis of benign and malignant thyroid nodules: 
preliminary experience. Eur J Radiol 2012; 81: 2678-2683.
